KYVIVY
Live / Applied — Third extension granted (statement of use) (as of 04 Nov 2025)
What this means for you
Not registered yet, but its 27 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98199140
- Mark type
- Stylized text
- Filed
- 27 Sept 2023
- Published for opposition
- 02 Apr 2024
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of blood conditions; Pharmaceutical preparations for the treatment of transplant diseases, illnesses, and conditions; Pharmaceutical preparations for renal transplant diseases, illnesses, and conditions; Pharmaceutical preparations for kidney diseases, illnesses and conditions; Pharmaceutical preparations for treatment of antibody mediated rejection in adult renal transplant recipients; pharmaceutical preparations to treat hematology diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of emphysema diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, acute respiratory distress syndrome, ARDS; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions, namely, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Owner
- CSL Behring L.L.C., King of Prussia, PA, US
- CSL Behring L.L.C., King of Prussia, PA, US
Prosecution history
- 05 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Nov 2025 — SOU EXTENSION 3 GRANTED
- 04 Nov 2025 — SOU EXTENSION 3 FILED
- 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 05 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 May 2025 — SOU EXTENSION 2 GRANTED
- 05 May 2025 — SOU EXTENSION 2 FILED
- 05 May 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Nov 2024 — SOU EXTENSION 1 GRANTED
- 04 Nov 2024 — SOU EXTENSION 1 FILED
- 04 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 04 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Apr 2024 — PUBLISHED FOR OPPOSITION